Quick Answer
Amphastar Pharmaceuticals, Inc. reported Cash and Equivalents of $170.18 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $170.18M | +12.2% |
| 2024 | $151.61M | +5.1% |
| 2023 | $144.30M | -7.6% |
| 2022 | $156.10M | +23.5% |
| 2021 | $126.35M | +36.4% |
| 2020 | $92.64M | +25.7% |
| 2019 | $73.69M | -14.7% |
| 2018 | $86.34M | +31.6% |
| 2017 | $65.59M | -9.3% |
| 2016 | $72.35M | +9.5% |
| 2015 | $66.07M | -2.6% |
| 2014 | $67.83M | +26.6% |
| 2013 | $53.59M | +6.7% |
| 2012 | $50.21M | -6.6% |
| 2011 | $53.74M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $216.26M | +12.6% | +15.2% |
| June 30, 2025 | $187.69M | -1.0% | +2.7% |
| March 31, 2025 | $182.78M | -9.1% | +20.6% |
| December 31, 2024 | $151.61M | +5.1% | -21.1% |
| September 30, 2024 | $192.12M | -28.0% | +1.3% |
| June 30, 2024 | $189.62M | +27.6% | -5.7% |
| March 31, 2024 | $201.15M | +13.9% | +39.4% |
| December 31, 2023 | $144.30M | -7.6% | -45.9% |
- Amphastar Pharmaceuticals, Inc. showed an increase of +12.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Amphastar Pharmaceuticals, Inc.’s cash and equivalents has grown by 216.7% (from $53.74 million to $170.18 million).
- The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: